1. Principal investigator, “Simple aspiration and drainage and intrapleural minocycline pleurodesis versus simple aspiration and drainage for the initial treatment of primary spontaneous pneumothorax: an open-label, parallel-group, prospective, randomised, controlled trial” (Lancet. 2013 Apr 13;381(9874):1277-82.) - Prospective, multiple centers, randomised, double-blind trial. - Has changed standard treatment guidelines for primary spontaneous pneumothorax by using minocycline pleurodesis as an adjunct. 2. Principal investigator, “A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2)” - Both enrollment number and randomization number rank first in Taiwan, which is the country with the most randomization number in this global competitive study so far. 3. Principal investigator, “Investigation of the Epigenetic Markers on Nucleosome for Detecting Non-small cell lung cancer of lungs” - Cooperated with multinational corporation, Volition RX. - Development of blood test for lung cancer screening. - Total case number exceeds 1,000. 4. Principal investigator, “Validation of Nu.Q biomarker panel in differentiating between high and low risk of cancer in nodules identified by LDCT screening”. - Cooperated with multinational corporation, Volition RX. - Verification of blood test for lung cancer screening. - Enrollment target of 500 cases has been achieved.